J&J Proposes Public-Private Initiative To Advance OTC Monograph Work
This article was originally published in The Rose Sheet
Executive Summary
An FDA guidance provides a viable framework for a public-private partnership to facilitate progress in the OTC monograph system, according to J&J consumer business executives. At the same FDA hearing on improving OTC drug review, CHPA leadership stressed that “moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades.”